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The two major autoimmune thyroid diseases (ATDs) include Graves’ disease (GD) and autoimmune thyroiditis (AT); both of
which are characterized by inﬁltration of the thyroid by T and B cells reactive to thyroid antigens, by the production of thyroid
autoantibodies and by abnormal thyroid function (hyperthyroidism in GD and hypothyroidism in AT). While the exact etiology
of thyroid autoimmunity is not known, it is believed to develop when a combination of genetic susceptibility and environmental
encounters leads to breakdown of tolerance. It is important to recognize thyroid dysfunction at an early stage by maintaining an
appropriate index of suspicion.
1.Introduction
Autoimmune thyroid disease (ATD) is the most common
autoimmune condition, aﬀecting approximately 2% of the
female population and 0.2% of the male population [1].
Its overall prevalence peaks in adulthood; it is also the
most common etiology of acquired thyroid dysfunction in
paediatrics.Itismorecommoninfemalesandusuallyoccurs
in early to mid-puberty [2, 3]. Optimal quantities of thyroid
hormone are critical to neurodevelopment and growth. The
paediatrician can often recognize thyroid dysfunction in
its early stages, by maintaining an appropriate index of
suspicion.
This review will analyze current opinions and options
regarding the etiology, evaluation, diagnosis, treatment, and
prognosis of ATDs in children.
1.1. Etiology. ATD arises due to complex interactions
between environmental and genetic factors, that are yet to
be completely deﬁned. ATD is multifactorial in that a genetic
predisposition combines with environmental risk factors to
promote disease.
Early evidence that ATD has a hereditary component
stems from studies of familial aggregation. Several studies
of young people with ATDs showed a deﬁnite genetic
propensity for thyroid autoimmunity to run in families [4].
Further evidence of the genetic control of ATDs comes from
the observation of twins. Monozygotic twins show a higher
concordance rate of disease than dizygotic twins. However,
even with identical twins the concordance rate is only about
50%, emphasizing that other important factors, such as the
environment, play a role in disease pathogenesis [5–7]. The
identiﬁed ATDs susceptibility genes can be divided into two
broad groups:
(1) immune modulating genes, and
(2) thyroid speciﬁc genes.
The immune modulating genes so far identiﬁed are:
HLA-DR, CTLA-4, CD40, and PTPN22. The cytotoxic T
lymphocyte-associated factor 4 (CTLA-4) gene is a major
negative regulator of T-cell activation [8]. CTLA-4 acti-
vation has been shown to suppress several experimental
autoimmune diseases. CD40 [9] is expressed primarily on
B cells and other antigen presenting cells (APCs) and
plays a fundamental role in B-cell activation inducing,
upon ligation, B-cell proliferation, immunoglobulin class
switching, antibody secretion, and generation of memory
cells. The lymphoid tyrosine phosphatase, encoded by the
protein tyrosine phosphatase-22 (PTPN22) gene, like CTLA-
4, is a powerful inhibitor of T-cell activation [10]. Recently,
linkage studies mapped ATDs susceptibility loci in two
thyroid speciﬁc genes, the thyroglobulin (TG) [11]a n dT S H
receptor (TSHr) genes [12], that represent the main targets
of the immune response in ATDs.2 Journal of Thyroid Research
Polymorphic variations of all the cited genes have been
identiﬁed and linked to ATDs susceptibility, but the existing
studies have often given inconsistent results, with some
showing associations and others not. One of the many
unexpected ﬁndings of these genetic studies is that most
of the identiﬁed genes have a very minor eﬀects. Indeed,
with the exception of the DRb1-Arg74 HLA variant, which
gave an odd ratio for Graves’ disease (GD) of >5, all the
other ATDs genes gave very low odd ratios of <1.5 [13];
on the other hand, family history is positive in about 50%
of patients with ATDs. It is usually supposed that a strong
genetic eﬀect on disease is related to the inheritance of many
genes with small eﬀect. Two alternative mechanisms have
beenproposed fortheﬁndingofverylowodd ratios formost
ATDs genes [4]: subset eﬀect and gene-gene interactions.
According to the “gene-gene interaction” model, two genes
with weak eﬀects (i.e., associated with low odd ratios)
interact, biologically resulting in a combined odd ratio that
is signiﬁcantly higher than the one expected with an additive
eﬀect alone. For example, two genes with odd ratios for
disease of 1.2 when inherited together would give an odd
r a t i oo f1 . 4 4( 1 . 2× 1.2), if there was only an additive eﬀect.
If there is an interaction between these two genes, the odd
ratio for disease will be signiﬁcantly higher. According to
the “subset eﬀect” model (also called genetic heterogeneity),
each of the genetic variants identiﬁed has a large eﬀect
resulting in a high odd ratio in a subset of the ATDs patients
studied.Onthecontrary,whenthesevariantsaretestedinthe
entire population of ATDs patients, their eﬀects are diluted,
resulting in much smaller odd ratios.
A recent twin study estimated that 79% of the liability
to the development of GD is attributable to genetic factors
[14]. Therefore, about 20% of the liability to develop
GD is due to nongenetic factors. Among the nongenetic
factors postulated to precipitate ATDs are iodine [15, 16]
and medications such as amiodarone [17] and interferon
α [18], infections, smoking, and stress. Amiodarone is a
benzofuranic-derivative iodine-rich drug widely used for the
treatment of tachyarrhythmias. It often causes changes in
thyroid function tests (typically an increase in serum T4
and rT3 and a decrease in serum T3 concentrations), mainly
related to the inhibition of 5 -deiodinase activity. In 14–18%
of amiodarone-treated patients, there is overt thyroid dys-
function,eitheramiodarone-inducedthyrotoxicosis(AIT)or
amiodarone-induced hypothyroidism (AIH). Both AIT and
AIH may develop either in apparently normal thyroid glands
or in glands with preexisting, clinically silent abnormalities.
PreexistingHashimoto’sthyroiditisisadeﬁniteriskfactorfor
the occurrence of AIH. The pathogenesis of iodine-induced
AIH is related to a failure to escape from the acute Wolﬀ-
Chaikoﬀ eﬀect due to defects in thyroid hormonogenesis
and, in patients with positive thyroid autoantibody tests,
to concomitant Hashimoto’s thyroiditis. AIT is primarily
related to excess iodine-induced thyroid hormone synthesis
inanabnormalthyroidgland(typeIAIT)ortoamiodarone-
related destructive thyroiditis (type II AIT), but mixed forms
frequently exist [17].
A few studies have shown seasonality [19, 20]a n d
geographic variation [21] in the incidence of GD, adding
evidence that infectious agents may trigger ATDs. Moreover,
several infectious agents have been implicated including
Yersinia enterocolitica [22, 23], Coxsackie B virus [24],
retroviruses [25, 26], and Helicobacter pylori [27].
By now, the strongest association of ATDs with an
infectious agent is with hepatitis C virus (HCV) [28]. In
most studies examining the frequency of thyroid disorders
in hepatitis C patients, approximately 10% of the patients
had positive autoantibodies prior to initiation of interferon
therapy [29, 30]. Pooling of data from all studies on
HCV infection and thyroid autoimmunity demonstrated a
signiﬁcant increase in the risk of ATDs in HCV patients [31].
Two main theories have been proposed for the induction
of autoimmunity by infectious agents: (1) the “molecular
mimicry” theory suggests that sequence similarities between
viral or bacterial proteins and self proteins can induce a
cross-over immune response to self antigens [32]; (2) the
“bystander activation” theory proposes that viral infection of
a certain tissue can induce local inﬂammation and cytokine
release, resulting in activation of autoreactive T cells, that
were suppressed by peripheral regulatory mechanisms [33].
2. Autoimmune Thyroiditis(AT)
The childhood prevalence of chronic autoimmune thy-
roiditis (AT) peaks in early to mid-puberty, and a female
preponderance of 2:1 has been reported [34]. Presentation
is rare under the age of 3 years, but cases have been described
even in infancy [35].
2.1. Terminology and Deﬁnitions. In 1912, Hashimoto
described four women with goiter and the apparent trans-
formation of thyroid into lymphoid tissue (struma lym-
phomatosa). These patients comprise the ﬁrst report of
Hashimoto’s disease, which we now recognize as a form
of AT. Improvements in the measurement of circulating
autoantibodies and ultrasonography have obviated the need
for biopsy in the diagnosis of AT. The term thyroiditis is
deﬁned as evidence of “intrathyroidal lymphocytic inﬁl-
tration” with or without follicular damage. Two types of
AT (also deﬁned as chronic lymphocytic thyroiditis) are
causes of persistent hypothyroidism: Hashimoto’s disease
(goitrousform)andatrophicthyroiditis(nongoitrousform).
Both are characterized by circulating thyroid autoantibodies
and varying degrees of thyroid dysfunction, diﬀering only
by the presence or absence of goiter. Transient thyroiditis
seems to be a variant presentation of AT. It is characterized
by an autoimmune-mediated lymphocytic inﬂammation of
the thyroid gland resulting in a destructive thyroiditis with
release of thyroid hormone and transient hyperthyroidism,
frequentlyfollowedbyahypothyroidphaseandfullrecovery.
The condition is particularly common in the postpartum
period, but it has been observed also in children. The
term chronic AT does not include subacute (de Quervain’s)
thyroiditis.
2.2. Pathophysiology. The activation of CD4 (helper) T-
lymphocytesspeciﬁcforthyroidantigensisbelievedtobethe
ﬁrst step in pathogenesis. Once activated, self-reactive CD4Journal of Thyroid Research 3
T cells recruit cytotoxic CD8 T cells as well as autoreactive B
cells into the thyroid. The three main targets of thyroid anti-
bodies are thyroglobulin (TG), thyroid peroxidase (TPO),
and the TSH receptor (TSHr). Anti-TPO antibodies have
been shown to inhibit the activity of the enzyme in vitro, but
direct cytotoxicity by CD8 T cells is believed to be the main
mechanismofhypothyroidisminvivo.Anti-TSHrantibodies
of the blocking type may contribute to hypothyroidism in a
minority of adult patients with the atrophic form of AT, but
this has not been proven in children. Histologically, goitrous
AT is characterized by diﬀuse lymphocytic inﬁltration with
occasionalgerminalcenters.Thyroidfolliclesmaybereduced
in size and contain sparse colloid. Individual thyroid cells
are often enlarged with oxyphilic cytoplasm (usually deﬁned
Hurthle cells). In contrast, the gland of atrophic AT is small,
with lymphocytic inﬁltration and ﬁbrous replacement of the
parenchyma [36].
2.3. Clinical Aspects. AT is usually suspected in the presence
of goiter, even in the absence of signs and symptoms of
thyroid dysfunction. It may also be diagnosed incidentally
during medical checkups, screening evaluation of children
with growth defects, or followup of children with associated
diseases, mainly Down syndrome, Turner syndrome, type 1
diabetes, and celiac disease [37–39]. Additionally, a recent
study [40] analyzed morpho-volumetric and functional
thyroid abnormalities in young patients with Williams
syndrome: 31.5% had subclinical hypothyroidism with TSH
above the upper normal limit and normal FT3 and FT4
concentrations, and 67.5% had morphological or volumetric
abnormalities of the thyroid gland at ultrasonography. Anti-
TPO antibodies and anti-TG antibodies were absent in all
patients, suggesting embrional defect of thyroid morpho-
genesis and/or a delayed maturation of the hypothalamic-
pituitary-thyroid axis, instead of an ATD, more common in
the other syndromes.
In all patients with associated diseases, AT is usually
detected in its initial phase when thyroid function is
preserved, with normal or only slightly elevated TSH levels.
At this stage, signs and symptoms of thyroid disease are
usually absent, but because worsening of thyroid function
is a possibility, early recognition of thyroid dysfunction is
necessary to prevent the negative eﬀects of hypothyroidism
on growth and metabolic function. The enlarged thyroid
gland usually is diﬀuse and nontender; sometimes the gland
may be ﬁrm [36]. As the disease progresses, subclinical
and then clinical hypothyroidism appears. Symptoms of
hypothyroidism may be subtle, even with marked biochemi-
cal derangement (Table 1). The initial history should investi-
gateenergylevel,sleeppattern,menses,coldintolerance,and
school performance. In addition to palpation of the thyroid,
assessment of the extra ocular movements, ﬂuid status,
and deep tendon reﬂexes are important components of the
physical examination. AT may be the initial presentation of
an autoimmune polyglandular syndrome, and the possibility
of coexisting autoimmune diseases such as type 1 diabetes,
celiac disease, Addison’s disease, and pernicious anemia
must be addressed by the past medical history. Screening
for other autoimmune diseases should be undertaken if
Table 1: Symptoms and signs of overt hypothyroidism.
Goiter
Poor linear growth with increased weight for height
Bone maturation delay
Pubertal disorders (pubertal delay or pseudoprecocious
puberty)
Irregular menstrual periods
Lethargy and/or impaired school performance
Fatigue
Bradycardia and decreased cardiac output
Constipation
Cold intolerance
Hypothermia
Fluid retention and weight gain (due to impaired renal
free water clearance)
Puﬃness of the face
Dry skin
Increased body hair
Delayed relaxation phase of the deep tendon reﬂexes
clinically indicated. Growth and pubertal development may
be deranged. Similar to other endocrine causes of growth
failure, linear growth is compromised to a greater degree
than weight gain, and the bone age is delayed [41, 42].
Hypothyroidism typically causes pubertal delay but may also
induce pseudoprecocious puberty, manifested as testicular
enlargement in boys, breast development, and/or vaginal
bleeding in girls [43–45]. This syndrome clinically diﬀers
from true precocity by the absence of accelerated bone
maturation and linear growth.
2.4. Diagnosis. The serum TSH concentration is elevated
in primary hypothyroidism and its determination is an
appropriate screening test for thyroid dysfunction. If the
diﬀerential diagnosis includes central hypothyroidism or
if the overall suspicion for overt hypothyroidism is high,
FT4 should be included. In mild hypothyroidism, serum
FT3 can remain in the normal range due to the increased
conversion of FT4 to FT3 by type 2 deiodinase and the
preferential secretion of FT3 by residual thyroid tissue under
the inﬂuence of high TSH levels [46]. For these reasons,
measurement of the serum T3 and FT3 concentration is
not a useful test in the diagnosis or monitoring of patients
with primary hypothyroidism. The presence of goiter or
high TSH levels should prompt the measurement of anti-
TPO antibodies. Anti-TPO antibodies are the most sensitive
screenforAT.Littlefurtherbeneﬁtisgainedbytheadditional
measurement of anti-TG antibodies, although they may be
added if anti-TPO titers are negative [47]. Ultrasonography
of the gland shows characteristic structural abnormalities
such as generalized hypoechoicity and disomogeneity, due
to inﬂammation and diﬀuse lymphocytic inﬁltration with
occasional germinal centers (pseudonodules). A diﬀuse4 Journal of Thyroid Research
ﬁbrosis of the gland can become evident at a later stage of
the disease [48].
We recommend thyroid ultrasound to conﬁrm AT diag-
nosis and to investigate the appearance of thyroid nodules
during followup, although it is not considered as a standard
of care.
The typical patient with hypothyroidism secondary to
AT will have an elevated TSH (“typically” over 10IU/mL),
al o wF T 4, and positive anti-TPO antibodies. In early
stages of the disease, TSH may be normal and anti-TPO
antibodies maybepositive withorwithoutgoiter.Later,TSH
elevation becomes modest (5–10IU/mL) with a normal FT4
(biochemical or subclinical hypothyroidism). Up to 90% of
patients with hypothyroidism secondary to AT are anti-TPO
antibody positive. It should be noted that 10–15% of the
general population are positive for anti-TPO antibodies and
that low titers (less than 1/100 by agglutination methods or
less than 100IU/L by immunoassays) are less speciﬁc for
ATDs [1].
If anti-TPO antibodies are absent, less common eti-
ologies of primary hypothyroidism should be considered:
transient hypothyroidism due to postsubacute thyroiditis,
hypothyroidism related to external irradiation [49], and
consumptive hypothyroidism due to the inactivation of
thyroid hormone by the paraneoplastic expression of type
3 iodothyronine deiodinase, mostly in vascular tumors [50].
Subclinical hypothyroidism is deﬁned as TSH elevation with
normal concentrations of circulating thyroid hormones (FT4
and FT3). The log-linear relationship between serum TSH
and FT4 explains how small reductions in serum FT4 lead to
large deviations in TSH. The majority of these patients are
asymptomatic, but studies in the adult population suggest
that individuals with the combined risk factors of TSH
level above the normal limit and positive thyroid antibodies
(anti-TG or anti-TPO) are at high risk for progression
to overt hypothyroidism. For this reason, we recommend
thyroidhormonereplacementinallpatientswithTSHvalues
>10IU/mL or with TSH values >5IU/mL in combination
with goiter or thyroid autoantibodies [51].
2.5. Therapy and Management. Levothyroxine (L-T4) is the
replacement therapy of choice. There are virtually no adverse
reactions; its good intestinal absorption and its long half-
life of 5–7 days allow oral administration once a day.
Althoughveryrare,thedevelopmentofpseudotumorcerebri
associated with the initiation of L-T4 has been described in
a small number of school-age children [52]. Some authors
advocate a graded approach to the initiation of L-T4 [53].
Alternatively, a starting dose can be estimated based upon
the patient’s age and ideal body weight (Table 2)[ 34]. The
medication’s long half-life insures a gradual equilibration
over the course of 5–6 weeks, and dosing should be indi-
vidualized on the basis of biochemical monitoring [34]. TSH
normalization is the goal of replacement. In our practice, we
aim to reach values in the lower part of the normal range
(0.5–2 micro IU/mL). This will usually be associated with an
FT4 in the upper half of the normal range. Thyroid function
tests should be obtained about 6–8 weeks after the initiation
or subsequent adjustment of the L-T4 dosage. Very high
Table 2: Recommended levothyroxine (L-T4) treatment doses.
Age Dose (mcg/kg/day)
0–3 months 10–12
3–6 months 8–10
6–12 months 6–8
1–3 years 4–6
3–10 years 3–4
10–15 years 2–4
>15 years 2–3
Adult 1.6–1.8
TSH levels at diagnosis can be associated with thyrotroph
hypertrophy and gradual suppression over the ﬁrst year of
treatment [54, 55]. Growth and sexual development should
be followed systematically as in any paediatric patient. Once
biochemical euthyroidism has been achieved, TSH can be
monitored every 4–6 months in the growing child and yearly
up to the attainment of ﬁnal height. If poor compliance
is suspected as the cause of treatment failure, FT4 should
be measured. A serum TSH greater than twice normal,
with a concomitant normal FT4 level, suggests intermittent
omission of the medication. A variety of conditions or
drugs may alter L-T4 requirements (Table 3). L-T4 should
be administered at least 20min before eating or ingestion
of any medication known to impair its absorption, such
as calcium and iron supplements, sucralfate, potassium-
binding resins, antacids containing aluminium, and bile-
acidsbindingresins.Allothermedicationsshouldbechecked
forinteractions,particularlywithantidepressantsandseizure
medications (Table 3). Parents of children with AT should be
advised that the hypothyroidism is likely to be permanent
and monitoring of thyroid function for all patients should
be lifelong. The prognosis for recovering lost linear growth
depends on the duration of the hypothyroidism as well as
the age at which treatment is started. If hypothyroidism
is longstanding, thyroid replacement will not recover all
lost stature. Similarly, if the diagnosis is made around
puberty, there may be limited time for recovering the
growth spurt before attaining ﬁnal height. If the onset of
childhood hypothyroidism occurs after age 2 to 3 years,
no permanent intellectual damage or neurologic deﬁcit is
probable. Children aﬀected by type 1 diabetes, celiac disease,
and Down, Turner, and Williams syndrome should undergo
annual thyroid function tests to ensure that hypothyroidism
has not become evident.
2.6. Natural History and Prognosis. The natural history of AT
in children and adolescents is not fully known. Few studies
have examined the spontaneous evolution of the disease
[56, 57]. A recent Italian retrospective study described the
outcome of 160 children aﬀected with AT followed for up
to 32.6 years in 20 paediatric endocrine clinics [58]. In
agreement with other reports [56, 57], TSH concentrations
showed large ﬂuctuations over time. Analyzing all the data
together, a trend toward progressively deteriorating thyroid
function was evident. However, at the last observation 84Journal of Thyroid Research 5
Table 3: Conditions that increase L-T4 requirements.
Pregnancy
Mucosal diseases of the small bowel
Jejuno-ileal bypass and small bowel resection
Drugs which impair L-T4 absorption (cholestyramine,
sucralfate, aluminum hydroxide, calcium carbonate, and
ferrous sulphate)
Drugs which may enhance CYP3A4 and thereby accelerate
L-T4 clearance (carbamazepine, rifampin, phenytoin,
estrogen, and sertraline)
Drugs which impair T4 to T3 conversion (amiodarone)
Conditions which may block type 1 deiodinase (selenium
deﬁciency due to dietary deﬁciencies as in phenylketonuria and
cystic ﬁbrosis)
Cirrhosis
patients (52.5%) still had a normal thyroid function or had
become euthyroid. The authors analyzed reliable prognostic
factors to predict disease evolution but found that clinical
measures, thyroid volume, and antibody concentrations
were similar in the group with normal TSH levels and the
group with elevated TSH levels. The number of patients
with type 1 diabetes was higher in the group with normal
TSH. This can be explained by the fact that patients with
autoimmune diseases are usually periodically assessed for
thyroid autoimmunity, and thus many patients with mild
asymptomatic forms of AT can be identiﬁed. Altogether,
the presence of associated diseases did not worsen the
prognosis, because at the end of the follow-up there was
no diﬀerence in the frequency of abnormally elevated TSH
between the groups with or without associated diseases. In
agreement with previous ﬁndings in children [59–61] and in
contrast with adults [62], the TSH level at baseline was not
a useful marker to predict disease evolution. Both thyroid
antibodies were signiﬁcantly higher at the last visit in the
group with deteriorating thyroid function; however, whereas
anti-TGantibodies werealreadyhigheratbaseline,anti-TPO
antibodies increased progressively with time. This ﬁnding
suggests that anti-TPO antibodies might represent a marker
of deteriorating thyroid function, in agreement with a pre-
vious report showing a good correlation between anti-TPO
antibodies levels and lymphocytic inﬁltration of the gland
[63]. The evaluation of patients, according to their ﬁnal
outcome, revealed that subjects with deteriorating thyroid
function had signiﬁcantly higher anti-TG antibodies, TSH
concentrations, and greater thyroid volume at presentation.
Nonetheless, these ﬁndings were not helpful in individual
patients. On the other hand, it should be remarked that at
5 years of followup, more than 50% of the patients remained
or became euthyroid.
We usually oﬀer a trial oﬀ L-T4 therapy to adolescents,
after the completion of growth and puberty. Thyroid func-
tion is retested 6–8 weeks after the stop of medication, to
determine if hypothyroidism is permanent and potentially
restart therapy.
2.7. Thyroid Nodules and Cancer in Patients with AT.
Although unusual in children and adolescents, thyroid nod-
ules are more often malignant in children than in adults [64,
65]. The prevalence of thyroid cancer among patients with
A Ti sam att e ro fc o n tr o v e r sy .A ft e rDai leyetal.[66]r e po rt ed
35 cases of AT among 288 patients with malignant thyroid
disease, postulating that the disorder could be considered
a precancerous lesion, other researchers seek an association
between AT and thyroid cancer. Subsequent studies [67–69]
reported a prevalence range of 1% to 30%. Data on the
occurrence of thyroid cancer in AT refer almost exclusively
to adults. The overall incidence of thyroid cancer among
childhood thyroid nodules was estimated to be 26.4% in
a review by Niedziela [69]. A recent study [64]a n a l y z e d
the relationship between AT, cancer, and thyroid nodules in
a large case series of paediatric patients. Thyroid nodules
were found in 115 of 365 patients with AT (31.5%): 69
subjects (60.0%) presented a solitary nodule, and 46 subjects
(40.0%) had multiple nodules. Thirty eight nodules (33%)
were palpable at clinical examination, and the presence
of all of them was conﬁrmed by ultrasonography. Eleven
cases of papillary carcinoma were detected on histologic
examination after total thyroidectomy, with 5 exhibiting
lymph node metastasis. Eight patients had multifocal cancer,
and 3 patients had single focus cancer. The prevalence
of male sex among patients with cancer was greater than
that among patients with AT (odd ratio: 2.95). The ﬁnd-
ing of lymphadenopathy and the progressive increase of
nodule diameter during L-T4 therapy represented the two
factors that were signiﬁcantly more frequent in patients
with thyroid cancer than in patients with a benign lesion.
Thyroid ultrasonography provided further useful diagnostic
information. Among patients with thyroid cancer, hypoe-
chogenicity seemed to predominate over other ultrasound
patterns, although it was common also in benign nodules.
Multinodularity was more frequent than uninodularity in
patients with cancer.
2.8. The Link between GD and AT. The observation that the
autoimmune attack against the thyroid gland could result
in two opposing clinical phenotypes, AT and GD, has been
intriguing for decades.
In AT, the lymphocytic inﬁltration of the thyroid gland
leads to apoptosis of thyroid cells and hypothyroidism. In
contrast, in GD the lymphocytic inﬁltration of the thyroid
leads to activation of TSHr-reactive B cells that secrete
TSHr-stimulating antibodies causing hyperthyroidism. The
etiology of AT and GD involves common pathways in which
thyroid reactive T cells escape tolerance and inﬁltrate the
thyroid,anduniquepathwaysinwhichthesethyroid-reactive
T cells either cause thyroid cell death (in AT) or stimulation
(in GD). Although GD and AT have diﬀerent clinical
phenotypes and the mechanisms leading to their dichotomy
are unknown, they are generally believed to share a number
of common etiological factors. There have been reports on
monozygotic twins in whom one twin had GD and the
other one had AT [70, 71]. Moreover, both conditions may
aggregate in the same family [72]o rm a ye v e nc o e x i s ti n
the same thyroid gland [73], and some individuals may6 Journal of Thyroid Research
progress from one form to the other. It is more frequent
that GD may spontaneously culminate in hypothyroidism
due to AT [74], while the development of GD from AT as
only occasionally been reported [75, 76]. On the other hand,
whole-genome scanning studies in humans have revealed
diﬀerences between the speciﬁc loci linked to, or associated
with, these two ATDs [77]. A recent study, performed in 109
children with GD at clinical onset [78], demonstrated that
hyperthyroidism might be preceded by AT presenting either
hypothyroidism or euthyroidism in at least 4 cases (3.7%).
After AT diagnosis, 3 of these patients underwent L-T4
therapy, which was continued for at least 1 year. In all these
cases, a subsequent thyroid function evaluation, performed
1–3monthspriortotheGDdiagnosis,hadevidencednormal
FT4 and TSH serum levels. The time interval between AT
diagnosis and GD presentation ranged from 1.5 to 2.8 years.
All of them exhibited both thyroid enlargement and other
clinical signs as well as symptoms of hyperthyroidism, while
exophthalmos and even mild eye signs were not evident in
any of them. Serum TSHr antibodies were higher in the
patients with no AT antecedents. The clinical course of GD
in patients with AT antecedents was not diﬀerent from the
one observed in those with no AT antecedents.
3.Graves’Disease (GD)
Robert Graves reported the clinical syndrome of goiter,
palpitations, and exophthalmos in 1835. In adults, GD
accounts for 60–80% of all patients with hyperthyroidism.
Hyperthyroidism is relatively rare in children (yearly inci-
dence of 8 per 1,000,000 children less than 15 years old and
1 per 1,000,000 children less than 4 years old), but GD is
by far the most common etiology. Girls are aﬀected four to
ﬁve times more frequently than boys, although no gender
diﬀerence is noted under 4 years of age [79].
3.1. Pathophysiology. GD shares many characteristics with
AT, including anti-TG antibodies, anti-TPO antibodies, and
antibodies against the sodium-iodine symporter. Hyperthy-
roidism is caused by thyroid-stimulating antibodies that
bind and activate TSHr, leading to follicular cell hyperpla-
sia and hypersecretion of thyroid hormones. Lymphocytic
inﬁltration of the thyroid is present. Sometimes, germinal
centers appear and develop as major sources of intrathyroid
autoantibodies. The lymphocytic inﬁltration and the accu-
mulation of glycosaminoglycans in the orbital connective
tissueandskincausetheextrathyroidalmanifestationsofGD
ophthalmopathy and dermopathy, respectively.
3.2. Clinical Aspects. The presentation of GD in childhood
may be insidious and a careful history often reveals a several
month history of progressive symptoms. Children may have
the same signs and symptoms of hyperthyroidism as do
adults, but most often they present with behavioral dis-
turbances: decreased attention span, diﬃculty concentrating
(which may lead to deteriorating performance in school),
emotional lability, hyperactivity, diﬃculty sleeping, and ner-
vousness. Typical cardiovascular ﬁndings include tachycar-
dia, palpitations, widened pulse pressure, and an overactive
Table 4: Clinical signs and symptoms of hyperthyroidism in
children.
Goiter
Exophthalmos
Acceleration of linear growth
Irritability
Impaired concentration and school performance
Headache
Hyperactivity
Fatigue
Palpitations
Tachycardia
Systolic Hypertension
Polyphagia
Increased frequency of bowel movements with diarrhoea
Weight loss
Heat intolerance
Increased perspiration
Tremor
Polyuria and polydipsia
precordium.Anychildwhohaspersistenttachycardiashould
beevaluatedforhyperthyroidism.Tremors,ashorteneddeep
tendon reﬂex relaxation phase, fatigue, and proximal muscle
weakness are possible neuromuscular manifestations of thy-
rotoxicosis. Despite an increase in appetite, aﬀected children
often lose weight and sometimes have diarrhoea, but usually
have frequent bowel movements associated with intestinal
motility (Table 4). Increased perspiration, warmth, and heat
intolerance tend to be late ﬁndings. Postpubertal girls often
have menstrual irregularities. A goiter is palpable in the
majorityofcases,characterizedbydiﬀuseenlargementwhich
issmooth,ﬁrm,andnontender.Thepretibialmyxedemathat
is a common feature of GD in adults is rare in children.
Extrathyroidal manifestations such as ophthalmopathy
and dermopathy are rarer in children than in adults and
tend to be less severe [80]. A 25–60% frequency of ocular
manifestations has been estimated in children, but usually
the ocular signs are mild such as lid retraction, a slight
proptosis that can be attributed to the inﬂammation and
muscle swelling rather than to inﬁltrative disease of the
orbital structures. As expected, these signs improve in most
patients after restoration of the euthyroid state [80]. Unique
to pediatric GD is the acceleration of linear growth and
bonematurationassociatedwithprolongedhyperthyroidism
[81, 82].
3.3. Diagnosis. Even if there may be national diﬀerences
in terminology, for the purposes of this study the term
thyrotoxicosis refers to the manifestations of excessive quan-
tities of circulating thyroid hormones. On the contrary,
hyperthyroidism refers only to the group of diseases which
are due to the overproduction of hormones by the thyroid
gland. An accurate diagnosis of GD is critical as antithyroidJournal of Thyroid Research 7
drugs have no role in the treatment of thyrotoxicosis
without hyperthyroidism. Thyrotoxicosis is recognized by
an elevation of serum FT4 with a decreased serum TSH
(typically <0.1 micro IU/mL). A determination of the FT3
level should be added if TSH is suppressed and the serum
FT4 is normal. In patients with early disease or in iodine-
deﬁcient patients, serum FT4 concentrations may be normal
o rr e d u c e dd e s p i t ee l e v a t e dl e v e l so fF T 3. Once biochemical
derangement has been documented, it is helpful to address
the duration of thyrotoxicosis to facilitate the diﬀerentiation
of GD from other causes of thyrotoxicosis. Onset may
be documented by prior laboratory studies or inferred
from the history. The diﬀerential diagnosis of thyrotoxicosis
includestransientthyroiditis,hyperfunctioningnodules,and
thyrotoxicosis factitia. In the majority of cases, the presence
of a symmetrically enlarged thyroid gland, coupled with the
chronicityofsymptoms,willbeadequatetoallowadiagnosis
(Table 5). If thyrotoxicosis has been present for more than 8
weeks,GDisbyfarthemostlikelyetiology.Theconstellation
of thyrotoxicosis, goiter, and orbitopathy is pathognomonic
of this condition, and no additional laboratory tests or imag-
ing studies should be necessary to conﬁrm the diagnosis. If
thyromegaly is subtle and eye changes are absent, a thyroid
echography should be performed. The radioactive iodide
uptake (RAIU) should be reserved for patients in whom a
discrete nodule(s) is palpable or evident at ultrasonography.
In patients with a toxic nodule, iodide uptake will localize
to the nodule and the signal in the surrounding tissue
will be low, secondary to TSH suppression. Thyrotoxicosis
factitia can be recognized by a low RAIU and serum TG,
in the presence of thyrotoxicosis and suppressed TSH levels.
If thyrotoxicosis has been present for less than 8 weeks,
transient thyrotoxicosis secondary to subacute thyroiditis or
the thyrotoxic phase of AT should be considered. An elevated
sedimentation rate supports subacute thyroiditis whereas
increased TPO and TG without increased TSHr antibody
titers supports the latter. RAIU was used in the past decades
to distinguish thyrotoxicosis due to the diﬀerent forms
of thyroiditis (increased release of thyroid hormone—low
RAIU), from the more common GD (increased production
of thyroid hormone—high RAIU), but the measurement of
TSHr antibodies may now oﬀer an eﬀective tool to make
the correct diagnosis, and RAIU is no more indicated for
diﬀerential diagnosis. Anti-TSHr antibodies are commonly
present in GD, whereas they are absent from AT and in
the other forms of thyrotoxicosis. The sensitivity of two
frequently used serum anti-TSHr antibody assays is cited
to be 75–96% for TBII (a competitive binding assay with
TSH) and 85–100% for TSAb measurements (a bioassay
of TSH receptor activation) in untreated GD patients. A
false negative rate of 10–20% has been documented for
serum anti-TSHr antibodies in GD, presumably due to
the inadequate sensitivity of the assays, or the exclusive
intrathyroidal production of autoantibodies.
In practice, the measurement of anti-TSHr antibod-
ies is routinely used in children to avoid RAIU, as the
combination of clinical signs, symptoms of thyrotoxicosis,
and positive autoantibodies, in the absence of a nodule
at ultrasonography, is virtually diagnostic of GD. There
Table 5: Diﬀerential diagnosis of thyrotoxicosis in children.
Thyrotoxicosis associated with sustained hormone overproduction
(hyperthyroidism). High RAIU
Graves’ disease
Toxic multinodular goiter
Toxic adenoma
Increased TSH secretion (TSH secreting adenomas)
Thyrotoxicosis without associated hyperthyroidism. Low RAIU
Thyrotoxicosis factitia
Subacute thyroiditis
Chronic autoimmune thyroiditis
Ectopic thyroid tissue (struma ovarii, functioning metastasis
of diﬀerentiated thyroid cancer)
is a subgroup of patients who have a subnormal but not
severely depressed TSH (usually 0.1–0.3 micro IU/mL)
and normal serum concentrations of thyroid hormones.
These patients are generally asymptomatic and the term
“subclinical hyperthyroidism” has been applied to their
condition. In elderly people, a low serum TSH concentra-
tion has been associated with an increased risk of atrial
ﬁbrillation, but no similar risks have been identiﬁed in
the paediatric population [83]. Furthermore, several studies
indicate that approximately half of patients with subclinical
thyrotoxicosis will experience a spontaneous remission [84].
The initial detection of a suppressed TSH concentration,
without elevated levels of thyroid hormone or associated
symptoms, should be addressed simply by repeating thyroid
function tests in 4–8 weeks. Assuming there are no speciﬁc
riskfactorssuchasahistoryofcardiacdisease,asymptomatic
children with subclinical hyperthyroidism can be followed
with the expectation that TSH suppression due to transient
thyroiditis will resolve spontaneously and that due to GD or
autonomous secretion will declare itself clinically over time.
3.4. Antithyroid Medications. The treatment of hyperthy-
roidism due to GD may be divided into two categories,
antithyroid medications and deﬁnitive therapy. The thion-
amide derivatives, methimazole (MMI) and propylthiouracil
(PTU), are the most commonly used antithyroid drugs
[85]. Both thionamides block thyroid hormone biosynthesis
and PTU, when used at doses over 450–600mg per day,
have the additional action of inhibiting the extrathyroidal
conversion of T4 to T3. The recommended starting dose is
0.5–1.0mg/kg per day for MMI and 5–10mg/kg per day
for PTU. Both drugs cross the placenta, although PTU does
so less and is preferred during pregnancy. Although both
are present in human milk, their concentrations are low,
and breastfeeding may be continued. Due to its longer half-
life, MMI can be administered once or twice a day, whereas
PTU should be administered three times a day. Over the 60
years that this medication has been used, reports of PTU-
related liver failure and death have been accumulated. The
risk of severe PTU-induced liver failure is estimated as 1
in 2000–4000 children. The number of children developing
reversible PTU-induced liver injury is estimated to be at8 Journal of Thyroid Research
least 1 in 200 children. Routine biochemical surveillance of
liver function and hepatocellular integrity is not useful in
identifying children who will develop liver failure. Children
appear to be at higher risk for PTU-induced liver injury than
adults. PTU should not be used as ﬁrst line therapy for the
treatment of GD in children. Current PTU use in children
should be stopped in favor of alternate therapies [86, 87].
For the speciﬁc situations of severe hyperthyroidism
or thyroid storm, PTU has been the preferred thionamide
because of its blockade of T4 to T3 conversion, through
the inhibition of type 1 iodothyronine deiodinase. In such
patients, a combination of high doses of PTU (up to 1200mg
per day divided in 4 doses) and inorganic iodine (SSKI: three
drops orally twice a day, for 5–10 days) will speed the fall in
circulating thyroid hormones. Some authors have advocated
a “block and replace” strategy of high-dose antithyroid
medication (to suppress all endogenous thyroxine secre-
tion) combined with levothyroxine replacement. One report
described a lower frequency of recurrence with this approach
[88]. However, all subsequent studies have failed to duplicate
this ﬁnding [89]. For the purpose of simplifying therapy
and minimizing the risk of adverse eﬀects, we usually prefer
monotherapy with a single antithyroid medication. After
FT4 level has fallen to the upper end of normal range, the
dose of antithyroid drug should be decreased by one half
or one third. Further dose adjustments are guided by serial
thyroid function tests, initially relying upon the FT4.A f t e r
pituitary TSH secretion recovers from suppression, the goal
of maintenance therapy is TSH normalization. The “block
and replace” approach is more complicated, but it can be
useful in small children when the titration and tapering of
the thionamide dose can be diﬃcult: even very small doses
are able to cause hypothyroidism, but the therapy cannot be
stopped too early, due to the elevated risk of recurrence. The
ﬁrst clinical response to medications is usually evident after
2–4 weeks. Weight loss stops or weight gain occurs. Beta-
adrenergic antagonists may be used as an adjunct during this
interval but, as the cardiovascular manifestations of hyper-
thyroidismaregenerallywelltoleratedinchildren,wereserve
this therapy for symptomatically signiﬁcant palpitations.
Antithyroid drugs are usually well tolerated, but side eﬀects
are seen more commonly in children than in adults. Thirty-
six serious complications and 2 deaths in children have
been reported to the FDA [90]. Agranulocytosis (deﬁned
as a granulocyte count less than 500/microL) is a serious
idiosyncratic reaction that can occur with either MMI or
PTU. For this reason, a baseline white count should be
obtained prior to the initiation of antithyroid drugs, since
mild neutropenia may be present in the GD patients prior
to the initiation of treatment, and it will be repeated 7–10
days after the start of therapy. Families should be advised
that fever, sore throat, or other serious infections may
be manifestations of agranulocytosis and therefore should
prompt the immediate cessation of antithyroid drugs, the
notiﬁcation of the physician, and a determination of white
blood cell count.
Reports of long-term remission rates in children are
variable, ranging anywhere from 30–60% [91]. Remission
rates are considerably less in prepubertal (17%) compared
to pubertal (30%) children, but a recent retrospective study
of 76 paediatric patients describes a 38% rate of long-
term remission achieved with more prolonged courses of
antithyroid medication (mean treatment duration of 3.3yr)
[92]. If the dose of antithyroid medication required to
maintain euthyroidism is 5mg per day of MMI (or less
for younger children) for 6 months to 1 year and the
serum TSH concentration is normal, a trial of medication
may be oﬀered. Antithyroid drugs can be discontinued
and TSH concentrations monitored at monthly intervals.
If hyperthyroidism relapses, as indicated by suppressed
T S Hl e v e l sw i t he l e v a t e dF T 4 levels, antithyroid medications
should be resumed or deﬁnitive therapy provided.
3.5. Deﬁnitive Therapy. The two options for the deﬁnitive
treatment of GD are I-131 and thyroidectomy. Both usually
result in life-long hypothyroidism, and there is no agreement
intheliteratureastotheirindications.Somecentersconsider
these modalities as options for the initial treatment of
paediatric hyperthyroidism [93–95]. However, considering
that a remission of GD occurs in a signiﬁcant percentage of
children, at the onset of the disease we recommend a long-
term trial with antithyroid medications (at least 2 years of
continuous therapy). If the disease relapses after stopping
therapy, one of the deﬁnitive therapeutical options should be
considered. If patient noncompliance prevents the successful
treatment, or both antithyroid medications must be discon-
tinued secondary to serious drug reactions, the choice of a
deﬁnitive therapy is appropriate. Thyroid ablation by I-131
is the ﬁrst choice deﬁnitive treatment in adults, but concerns
over the potential long-term complications of paediatric
radiation exposure have made endocrinologists cautious in
applying this approach to children [96]. The literature about
GD in adults describes an increased relative risk for the
development of stomach cancer (1.3 fold) and breast cancer
(1.9 fold), but no large, long-term, follow-up studies of
patients treated under 16 years of age have appeared [97]. It
isestimatedthatmorethan1000childrenhavereceivedI-131
for the treatment of GD. To date, there are no reports of an
increase in the incidence of thyroid carcinoma or leukaemia
in this population [96, 97]. Despite the reassurances of
these reports, experience with X-rays and the Chernobyl
nuclear power plant accident indicate that the carcinogenic
eﬀects of radiation to the thyroid are the highest in young
children [98, 99]. This argues for continued surveillanceand,
for children who fail antithyroid medication, the provision
of an I-131 dose adequate to destroy all thyroid follicular
cells. Some institutions administer an empiric dose of 3–15
millicuries, or a dose based upon the estimated weight of the
gland (50–200 micro CI per gram of thyroid tissue) [95–97].
Eﬃcacy is dependent upon both thyroid uptake and mass,
and it is more useful to prescribe a dose which will provide
approximately 200 micro Ci/g estimated weight in the gland
at 24 hours. Antithyroid drugs should be discontinued for 3
days prior to the administration of I-131. For children who
are unable to swallow a capsule, a liquid preparation of I-131
is available
Dose =
200 micro Ci/g ×g(thy) ×100
%u p t a k ei n2 4h
. (1)Journal of Thyroid Research 9
The frequency of acute side-eﬀects is low although vomiting
has been frequently described in paediatric patients [95].
One prospective study of 443 patients ranging from 15 to 85
years of age has raised the concern that I-131 may worsen or
precipitate the development of Graves’ ophthalmopathy in
approximately 15% of cases [100]. Severe ophthalmopathy
is less common in paediatric GD, but a study addressing
the risk of this presentation in children is not available.
The current paediatric literature suggests that the rate of
ophthalmologic exacerbation is similar amongst the various
treatment modalities: 3% after I-131, 2% with thionamide
derivatives, and 9% after subtotal thyroidectomy [88]. A
short course of glucocorticoids is appropriate if there is
rapid progression of ophthalmopathy or as prophylaxis
prior to radioiodine in children with pre-existing severe
ophthalmopathy. Baseline opthalmological assessment at the
onset of treatment is advisable.
Thyroidectomy is rarely used electively for the deﬁnitive
therapy of GD, except with massive thyromegaly (over eight
t i m e sn o r m a ls i z eo rt h y r o i dw e i g h t>80g) or for patients
in whom coexisting nodules are suspicious for carcinoma by
ﬁne needle aspiration. A meta-analysis of the paediatric lit-
erature provided the following analysis of surgical treatment:
subtotal thyroidectomy relieved hyperthyroidism in 80% of
patients, with 60% becoming hypothyroid. Total thyroidec-
tomy cured hyperthyroidism in over 97% of patients with
nearly universal hypothyroidism. The overall complication
rate in children included a 2% incidence of permanent
hypoparathyroidism, a 2% incidence of vocal cord paralysis,
and a 0.08% mortality [90]. One large institution has
published a series of 82 children treated surgically over 14yr
with much better results. Bilateral subtotal resection was
the most frequently performed operation (86%) and, with
a median followup of 8.3yr. A recurrence rate of 6% is
reported, while no cases of permanent recurrent laryngeal
nerve palsy, permanent parathyroid disease, or death were
observed [101]. The diﬀerence between the average compli-
cation rate and those in a single institution emphasizes the
importance ofskill andexperience in theperformanceofthis
procedure [102]. Postoperative hypothyroidism is expected
and it is easily treated, and all GD patients require life-long
monitoring. We suggest to consider thyroidectomy only for
patients who have persistently failed medical management
or those whose parents or physicians do not wish to proceed
with radioiodine therapy. Based on the results to date, I-131
therapy is an acceptable alternative if the surgical options
are undesirable. I-131 is recommended for all patients who
recur following surgery, due to the high complication rate of
secondary thyroidectomy [103].
3.6. Neonatal GD. Thyroid hormones are necessary for
optimal foetal and neonatal development, and the risk of
malformations may be increased in the newborns to hyper-
thyroid mothers [104, 105]. Lack of thyroid hormones for
more than a few weeks, during vulnerable periods of devel-
opment, involves a risk of permanent cerebral impairment
[106]. Conversely, excess amounts of thyroid hormone are
associated with increased risk of foetal death and may lead
to accelerated bone maturation leading to early epiphyseal
fusion and growth cessation. Also long-term exposure may
lead to ostepenia in adolescence and adulthood [107]. Only
0.6% of infants born to mothers with a history of GD will
develop neonatal hyperthyroidism, due to the transplacental
passage of thyroid-stimulating immunoglobulins. Even after
deﬁnitive treatment by I-131 or thyroidectomy, women
with a history of ATDs are at risk for foetal and neonatal
thyroid dysfunction secondary to the persistence of maternal
autoantibodies. The pregnancy of such women should be
considered high risk, and the care should be coordinated
between an experienced obstetrician and an endocrinologist.
Foetal heart rate and growth should be monitored by
regular prenatal ultrasounds. The measurement of anti-
TSHr antibodies during at-risk pregnancies has been recom-
mendedasapredictorforthedevelopmentoffoetal/neonatal
GD [108]. Highly experienced ultrasonographers can often
visualize the foetal thyroid. The presence of foetal goiter,
tachycardia, and intrauterine growth retardation suggests
foetal hyperthyroidism. In these rare patients, antithyroid
drugs are administered to the mother to control foetal
hyperthyroidism, this will keep the foetus euthyroid until
birth. After birth, the antithyroid drugs from the mother
will disappear from the foetal circulation within the ﬁrst
days of life. After some delay, neonatal hyperthyroidism may
developandremainuntilthematernalantibodiesarecleared.
Paediatricians should be aware that the use of maternal
antithyroid medications near the time of delivery or the co-
transfer of maternal anti-TSHr blocking immunoglobulins
may delay the appearance of neonatal GD [107]. For high-
risk infants, such as those born to mothers with high levels of
anti-TSHr stimulating antibodies or those with a history of
an aﬀected sibling, clinical monitoring and thyroid function
tests at birth and at 1 and 2 months of age are recommended
[109]. An additional set of laboratory tests at 1 week of age
is indicated for infants who have been exposed to maternal
antithyroid drugs in the third trimester. Aﬀected infants
are often ﬂushed, diaphoretic, and hyperkinetic. Goiter is
common and, when severe, can endanger the infant’s airway.
Diarrhoea, vomiting, poor weight gain, and a transient
exophthalmos may be seen. Arrhythmias and/or congestive
heartfailurecandevelop andrequiretreatmentwithdigoxin.
Serum for conﬁrmatory thyroid function tests (TSH, FT4)
should be obtained and treatment initiated immediately.
PTU (5–10mg/kg per day) or MMI (0.5–1.0mg/kg per day)
may be administered, orally or by gastric tube, in divided
doses every 8 hours. MMI is preferred following reports of
serious PTU toxicity. Inorganic iodine will speed the fall
in circulating thyroid hormone, using saturated solution of
potassium iodide (SSKI) (48mg iodide/drop) at the dose of
one drop per day. Iopanoic acid or sodium ipoiodate have
also been used for their iodine content and their capacity
to inhibit the activation of T4 to T3. As in older patients,
adjunctive therapy with beta-blockers (propranolol: 2mg/kg
per day—in 4 doses) and glucocorticoids (prednisone:
2mg/kg per day—in 2 doses) may be helpful in severe
cases. Cardiac failure may occur in some cases and require
treatment with digoxin. During the period of foetal and
neonatal hyperthyroidism, the pituitary TSH secretion has
been suppressed and the phase of neonatal hyperthyroidism10 Journal of Thyroid Research
may be followed by a phase of secondary hypothyroidism,
until pituitary TSH secretion is restored.
The cumulative morbidity of neonatal Graves was esti-
mated to be as high as 25% in the past, although it appears to
be considerably lower today [108, 109]. Potential long-term
morbidity includes growth retardation, craniosynostosis,
impaired intellectual function, and central hypothyroidism.
The half-life of maternal immunoglobulin is approximately
14 days, so most cases of neonatal Graves will resolve
after 3–12 weeks (depending upon the initial levels of anti-
TSHr antibodies). The history of maternal illness is critical.
Adolescent women who have GD should know that, even if
they are “cured,” when they become pregnant, their babies
eventually will be at risk.
The diﬀerential diagnosis of neonatal thyrotoxicosis
includes the McCune-Albright syndrome, activating muta-
tions of the TSH receptor and thyroid hormone resistance
syndrome [109, 110]. These non-autoimmune etiologies
are rare but should be considered if thyrotoxicosis persists
beyond 3 months of age.
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